PMID- 37091120
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240917
IS  - 2045-8932 (Print)
IS  - 2045-8940 (Electronic)
IS  - 2045-8932 (Linking)
VI  - 13
IP  - 2
DP  - 2023 Apr
TI  - Prevalence of pulmonary hypertension in patients with COVID-19 related lung 
      disease listed for lung transplantation: A UNOS registry analysis.
PG  - e12228
LID - 10.1002/pul2.12228 [doi]
LID - e12228
AB  - COVID-19 related lung disease (CRLD) has emerged as an indication for lung 
      transplantation (LT) in highly select patients. The prevalence and prognostic 
      implication of coexisting pulmonary hypertension (PH) in patients with CRLD 
      listed for LT is not known. Adult patients in the United Network for Organ 
      Sharing database listed for LT for COVID-19 related acute respiratory distress 
      syndrome or fibrosis through March 2022 were identified. The prevalence and 
      impact of precapillary PH on pre- and posttransplantation survival was 
      determined. Time-to-event analysis was used to compare outcomes between those 
      with and without precapillary PH. We identified 245 patients listed for LT for 
      CRLD who had right heart catheterization data available at the time of registry 
      listing. Median age of the cohort was 54 years (interquartile range [IQR]: 46, 
      60), 56 (22.9%) were female, and the median lung allocation score was 81.3 (IQR: 
      53.3, 89.4). The prevalence of precapillary PH at the time of transplant listing 
      was 27.9%. There was no significant difference in pretransplant mortality in 
      patients with and without precapillary PH (sHR: 0.5; 95% confidence interval 
      [CI]: 0.1-1.7, p = 0.261). A total of 187 patients ultimately underwent LT; of 
      those, 60 (31.0%) were identified as having precapillary PH during the waitlist 
      period. Posttransplantation survival was similar between patients with and 
      without pretransplant precapillary PH (hazard ratio: 0.96; 95% CI: 0.2-3.7, 
      p = 0.953). We observed a high rate of concomitant precapillary PH in patients 
      listed for LT for CRLD. Though common, coexisting precapillary PH was not 
      associated with a significant difference in either pre- or post-transplantation 
      outcomes.
CI  - (c) 2023 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on 
      behalf of Pulmonary Vascular Research Institute.
FAU - Thomas, Christopher
AU  - Thomas C
AUID- ORCID: 0000-0001-7033-2404
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Chandel, Abhimanyu
AU  - Chandel A
AUID- ORCID: 0000-0003-4879-1983
AD  - Department of Pulmonary and Critical Care Medicine Walter Reed National Military 
      Medical Center Bethesda Maryland USA.
FAU - King, Christopher S
AU  - King CS
AUID- ORCID: 0000-0003-3101-319X
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Aryal, Shambhu
AU  - Aryal S
AUID- ORCID: 0000-0002-3753-4378
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Brown, A Whitney
AU  - Brown AW
AUID- ORCID: 0000-0003-4332-4112
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Khangoora, Vikramjit
AU  - Khangoora V
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Nyquist, Alan
AU  - Nyquist A
AUID- ORCID: 0000-0002-2809-2416
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Singhal, Anju
AU  - Singhal A
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Fonseca, Onix Cantres
AU  - Fonseca OC
AUID- ORCID: 0000-0001-8205-6195
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Shlobin, Oksana
AU  - Shlobin O
AUID- ORCID: 0000-0003-4131-8499
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
FAU - Nathan, Steven D
AU  - Nathan SD
AUID- ORCID: 0000-0002-6270-1617
AD  - Inova Heart and Vascular Institute, Advanced Lung Disease and Transplant Program 
      Inova Fairfax Hospital Falls Church Virginia USA.
LA  - eng
PT  - Journal Article
DEP - 20230401
PL  - United States
TA  - Pulm Circ
JT  - Pulmonary circulation
JID - 101557243
PMC - PMC10114532
OTO - NOTNLM
OT  - Covid-19
OT  - lung transplantation
OT  - pulmonary fibrosis
OT  - pulmonary hypertension
COIS- Steven D. Nathan is a consultant for United Therapeutics, Roche, Bellerophon, and 
      Merck. He is on the speaker bureau for United Therapeutics and 
      Boehringer-Ingelheim. Oksana Shlobin is a consultant for United Therapeutics, 
      Janssen and Altavant, and serves on the speaker bureau of United Therapeutics, 
      Bayer and Janssen. Christopher S. King is a consultant for United Therapeutics, 
      Actelion, Altavant, Merck and Boehringer-Ingelheim. The other authors declare no 
      conflicts of interest.
EDAT- 2023/04/24 06:41
MHDA- 2023/04/24 06:42
PMCR- 2023/04/01
CRDT- 2023/04/24 03:51
PHST- 2022/11/14 00:00 [received]
PHST- 2023/03/11 00:00 [revised]
PHST- 2023/04/09 00:00 [accepted]
PHST- 2023/04/24 06:42 [medline]
PHST- 2023/04/24 06:41 [pubmed]
PHST- 2023/04/24 03:51 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - PUL212228 [pii]
AID - 10.1002/pul2.12228 [doi]
PST - epublish
SO  - Pulm Circ. 2023 Apr 1;13(2):e12228. doi: 10.1002/pul2.12228. eCollection 2023 
      Apr.